Articles tagged with Vaccine Development
The Jordan Report 20th Anniversary outlines significant advancements in vaccine research for diseases like HIV/AIDS, tuberculosis, malaria, and bioterrorism threats. The report emphasizes the importance of vaccines in preventing illness and death from infectious diseases.
A new study reveals dispersin, a protein on the surface of E. coli bacteria, helps promote its ability to survive and spread in the gut. Dispersin is now being explored as a potential vaccine candidate due to its strong immune response-provoking properties.
The HHS has awarded contracts to Avecia and VaxGen Inc. to develop a new anthrax vaccine that can provide immunity in three or fewer doses, reducing administration time. The vaccine will be produced using recombinant DNA technology and is expected to protect individuals from anthrax spores even if administered shortly after exposure.
A team of researchers at the University of Toronto has identified a protein and developed a prototype vaccine that shows promise in treating Sjögren syndrome. The vaccine was able to stop disease progression even after the condition had fully developed.
The European Molecular Biology Laboratory highlights the potential for genomic research to combat tropical diseases. However, commercial interest in developing treatments has been limited, and it will be necessary to combine efforts from not-for-profit organizations and private funds to support research in developing countries.
The University of Maryland Biotechnology Institute has licensed its DNA Bactofection technology to Microscience, enabling the delivery of DNA vaccines for viral diseases and cancers. Microscience will use the technology to develop a range of DNA vaccines, including those for typhoid, travellers' diarrhea, and hepatitis B virus infection.
A new HIV vaccine candidate has shown promising results, targeting a shared characteristic of all HIV strains and generating antibodies that neutralize a wide range of isolates. The complex could serve as a useful model for HIV vaccine development, bringing researchers closer to their goal of developing an effective vaccine.
Researchers have pinpointed the cause of hepatitis A virulence by identifying two key genes, 2C and VP1/2A. The discovery may lead to the development of a live, attenuated HAV vaccine that could be more effective and affordable for widespread use.
A team of Los Alamos researchers suggests using a consensus sequence of the HIV-1 virus as a basis for vaccines, rather than geographically specific strains. This approach aims to target common vulnerabilities in multiple strains of the virus.
Researchers discovered that an inactivated chickenpox vaccine may prevent healthy elderly people from developing shingles and protect transplant recipients against viruses and bacteria. The vaccine boosted memory T cells to mount an attack during the transplant and recovery, reducing shingle risk.
A new pneumococcal vaccine has been shown to significantly reduce the incidence of pneumonia and invasive disease in children in Soweto, South Africa. The vaccine, which includes two additional strains of pneumococcus prevalent in developing countries, reduced pneumonia by over 20% and invasive disease by 50-80%.
A new vaccine targeting ticks' gut wall could significantly reduce their fertility and larval survival, decreasing the risk of diseases like Lyme disease and tick-borne encephalitis. The development comes as tick-borne diseases are increasing in the UK and becoming more prevalent globally.
The American Chemical Society is examining scientific connections between the US and Cuba, with a focus on fostering Cuban-American research partnerships. Cubans and scientists with Cuban connections will discuss topics such as chemical education and nanotechnology.
A University of Florida researcher has developed a feline AIDS vaccine that the federal government has approved for commercial use. The vaccine, expected to be available this summer, is based on viruses from long-term nonprogressor cats and may aid in human HIV development.
Researchers at Virginia Tech will develop plant-expressed antigens and adjuvants to create affordable, effective vaccines. The goal is to produce inexpensive, disease-fighting vaccines through plant-based delivery systems.
A recent decision by NIAID has halted a proposed Phase III HIV vaccine efficacy trial, citing concerns about the level of CD8 cellular immune response. However, a new trial will proceed with a similar vaccine combination, ALVAC-HIV and AIDSVAX, to assess its efficacy in Thailand.
Researchers at Dartmouth have discovered a mutant strain of the T. gondi parasite that can provide protection against the normal parasite, while also being harmless to infected individuals. The mutant strain was created by inactivating a key enzyme in its biochemical pathway, rendering it unable to cause disease.
A new malaria vaccine, RTS,S/AS02, has demonstrated significant protection against natural P. falciparum infection in a randomised trial. The vaccine showed an overall efficacy of 34% after three doses, with increased effectiveness seen when a fourth dose was administered a year later.
The UCSB researchers have developed a cross-protective Salmonella vaccine using the DNA adenine methylase technology, which is also being explored for use in other bacterial and viral pathogens. This breakthrough offers significant potential for combating biowarfare agents and could render current vaccines obsolete.
A study by René Verreault and colleagues found that past vaccine exposure was associated with a reduced risk of developing Alzheimer's disease. The researchers used multivariate logistic regressions to compare vaccinated and non-vaccinated subjects, adjusting for age, sex, and education.
A new study is testing a diluted form of the traditional smallpox vaccine, aiming to increase available doses. Participants will receive either the full or reduced dose and be monitored for signs of successful vaccination.
Yale scientists have successfully immunized mice against West Nile virus, providing a promising lead for developing a vaccine for humans. The vaccine was developed using a protein found in the virus and showed complete protection against the disease.
A new AIDS vaccine developed by Yale researchers has shown promising results in protecting monkeys from the disease. The vaccine, which uses a common livestock virus vector, was highly effective in animal models and protected vaccinated monkeys for up to 14 months.
Dr. Tramont takes helm of DAIDS, a successful program critical to understanding HIV causes and creating antiretroviral drugs, with a focus on building on its legacy
A study found that people with late-onset dementia had lower intelligence scores as children compared to those without the disease. The researchers identified 59 patients with early-onset dementia and a comparison group, suggesting that lower childhood intelligence may be a risk factor for late-onset Alzheimer's disease.
Baltimore researchers will develop a new type of measles vaccine protecting infants younger than 9 months old, reducing global suffering and death rate from measles. A DNA vaccine approach using genetic material of the virus will be tested in humans to determine its effectiveness.
The Blueprint for TB Vaccine Development identifies the TB crisis as a global health priority and encourages an international collaborative effort to develop a vaccine. The report details three different vaccine concepts currently being developed: live, attenuated vaccines; subunit vaccines; and naked DNA vaccines.
Scientists at NIH and Whitehead Institute have grown malaria parasites in fruit flies, creating a model for studying parasite development in insects. The new model has identified a part of the insect immune system that naturally attacks malaria parasites.
The National Institute of Allergy and Infectious Diseases has launched four public-private partnerships to accelerate the development of promising HIV/AIDS vaccines. The partnerships aim to tap into the skills of both private industry and academic research centers, with a focus on developing vaccines for use around the world.
Maternal mortality remains a global health problem, despite significant international efforts. A new $4.95 million grant will aid in developing tools to diagnose and treat ectopic pregnancy, prevent preeclampsia, and identify women at risk of life-threatening infections.
The companies identified a family of proteins called Potassium Channel Interacting Proteins (KChIPs) that regulate A-type potassium channels, which control brain electrical signals. These KChIPs may lead to the development of new therapeutics for CNS disorders with minimal side effects.
Researchers created a transgenic rat model with human CETP to study atherosclerosis. The study showed that elevated CETP contributes to the development of atherosclerosis, supporting the use of an antibody-based vaccine to raise HDL cholesterol levels.
Researchers have developed a new method to explore autoimmune mechanisms in chronic Lyme disease, which could lead to better diagnosis and treatment. The technique identifies specific bits of the Lyme agent that trigger an immune response against the body's own cells.
The AVANT rotavirus vaccine demonstrated nearly 90% efficacy in preventing rotavirus disease in infants, surpassing existing vaccines' 49-68% efficacy rates. The vaccine was also found to be safe and immunogenic, with minimal side effects reported.
Researchers at The Wistar Institute are developing vaccines targeting the mucosal immune system to prevent HIV-1 and human papilloma virus infections. They aim to induce neutralizing antibodies and killer T cells to prevent cancerous transformations in cells, with a focus on cervical cancer caused by HPV.
The Wistar Institute's Regeneration Symposium will feature talks on epimorphic regeneration, limb regeneration, and the role of ependymal cells in spinal cord regeneration. Experts like David Stocum, Alejandro Sanchez Alvarado, and Susan V. Bryant will share their research findings.
The Wistar Institute hosted a symposium on regenerative biology, featuring experts discussing recent advances in understanding regeneration in metazoans, stem cells, and nervous systems. Key findings included insights into limb regeneration, spinal cord repair, and muscle cell replacement.
Dr. Keith Wailoo, a UNC associate professor, has been awarded a $1 million James S. McDonnell Centennial Fellowship to study disease and biomedicine in the 20th century. He will investigate how people's ideas about illnesses like breast cancer and sickle cell anemia have changed over time.
BioStratum's gene-attenuated virus vaccines protect macaque monkeys against HIV-1-based viruses. The study demonstrates the efficacy of two vaccines in preventing AIDS development in 11 out of 12 monkeys.
Researchers at The Wistar Institute have discovered two genes, Alphav and Beta3, that play a crucial role in melanoma development. These findings suggest that blocking the activity of the vitronectin receptor could be an effective way to prevent cancer progression.
Scientists have developed a new TB vaccine candidate that uses recombinant BCG strains to secrete pore-forming listeriolysin, improving its ability to stimulate CD8 T cells. This could lead to better protection against M. tuberculosis infection and potentially halve the estimated 2050 global TB cases.
A human clinical trial of an edible vaccine has shown promising results, indicating that consumption can result in immunity to specific diseases. The vaccine was tested on volunteers who ate genetically altered potatoes and showed a significant immune response, with antibodies found in both blood and stool samples.
Dr. Richard Facklam, CDC Lab Chief, receives award for his contributions to clinical microbiology research, focusing on streptococci identification and pneumococcal vaccine development. He has also worked on antimicrobial resistance studies in developing countries.
The company has validated the VEGF receptor as a key target in pathological angiogenesis and expects to submit an Investigational New Drug (IND) Application for clinical trials in cancer by the end of 1998. RPI.4610 has shown activity in multiple animal models, including inhibition of tumor growth and metastasis.